Sickle Cell Treatment Developed at LA BioMed Enters Phase 3 Clinical Trial

Published July 27, 2010

Sickle Cell Treatment Developed At LA BioMed Enters Phase 3 Clinical Trial
An experimental treatment for sickle cell disease developed at the Los Angeles Biomedical Research Institute (LA BioMed) has entered Phase 3 clinical trials, David I. Meyer, PhD, LA BioMed president and CEO have announced . Researchers throughout the U.S. have begun administering the sickle cell treatment developed by investigators led by Yutaka Niihara, MD, MPH, at LA BioMed and licensed to …
Read more on Medical News Today

Aggressive Treatment for Prostate Cancer Is the Norm
More than 75% of men diagnosed with low-risk prostate cancer undergo aggressive treatment — either complete removal of the prostate or radiation therapy, according to a new study.
Read more on WebMD

‘More targeted’ treatment key to helping crack users: Study
Targeted prevention and treatment programs can help crack users in smaller communities, according to a study from a Simon Fraser University researcher.
Read more on Canada.com